Open for inclusion

A Multicenter, Open Label, Phase 1 Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INC280 Tablet Formulation With Food in Patients With cMET Dysregulated Advanced Solid Tumors

Cancer type: Multiple diagnosis, Solide tumores

Phase: I

Principal Investigator: Yachnin Jeffrey

Country: SE

Keywords: Sweden, Stockholm, cMET

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02925104?lead=Novartis&id=CINC280A2108&rank=1